+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurorehabilitation Market by Type, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 181 Pages
  • November 2021
  • Region: Global
  • Allied Market Research
  • ID: 5533797
The global neurorehabilitation market was valued at $ 1,097.69 million in 2020 and is projected to reach $ 2,45million by 2030 registering a CAGR of 8.3% from 2021 to 2030.

Neurorehabilitation is an advanced recovery treatment method designed for those individuals who have nervous system related injury or disorder, which helps to restore their lost abilities, supervised by doctors. Neurorehabilitation devices involve non-invasive brain stimulators, brain-computer interfaces, neuro-robotic systems, and wearable devices. Neurorehabilitation devices facilitate to reduce symptoms and improve neurological related function. This device is most commonly used for physiotherapy and it improves patient quality life. For handling this device and help patient to improved neuro function, skilled professionals are required. There are various types of devices available in the market such as neuro-robotic devices, non-invasive stimulators, and brain-computer interfaces.

The major factors that drive growth of the neurorehabilitation market include increase in prevalence of neurological diseases such as brain stroke, Parkinson's disease, multiple sclerosis, spinal cord injury, traumatic brain injury, cerebral palsy, and others. Increase in awareness about neurorehabilitation devices among population. In addition, growth in funding for R&D and rise in product approvals of neurorehabilitation devices by regulatory authorities further boost growth of the neurorehabilitation market. However, high cost of neurorehabilitation devices and lack of adequate skilled professionals to operate neurorehabilitation devices and perform neurorehabilitation therapies in the healthcare industry hamper growth of the market. In contrast, rise in demand for telerehabilitation is expected to offer lucrative growth opportunities for players in the neurorehabilitation market.

The global neurorehabilitation market is segmented on the basis of type, application, end user, and region to provide a detailed assessment of the market. By type, it is segmented into neuro-robotic devices, non-invasive stimulators, and brain-computer interfaces. By application, it is segmented into brain stroke, Parkinson's disease, multiple sclerosis, spinal cord injury, traumatic brain injury, cerebral palsy, and others. On the basis of end user, it is categorized into rehabilitation centers, hospitals, and clinics. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the neurorehabilitation market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of neurorehabilitation used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Type

  • Neuro-Robotic Devices
  • Non-Invasive Stimulators
  • Brain-Computer Interfaces

By Application

  • Brain Stroke
  • Parkinson's Disease
  • Multiple Sclerosis
  • Spinal Cord Injury
  • Traumatic Brain Injury
  • Cerebral Palsy
  • Others

By End-User

  • Rehabilitation Centers
  • Hospitals
  • Clinics

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East and Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Bionik Laboratories Corp.
  • BioScience Managers Ltd (Rex Bionics Ltd)
  • Bioventus (Bioness Inc.)
  • DIH (Hocoma AG)
  • Ekso Bionics Holdings, Inc.
  • Eodyne
  • Neofect
  • Neuro Rehab VR
  • Reha Technology AG
  • ReWalk Robotics Ltd.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increasing Prevalence of Neurological Diseases
3.5.1.2. Increasing Funding for R&D Activities
3.5.1.3. Rising Product Approvals by Regulatory Authorities
3.5.2. Restraint
3.5.2.1. High Cost of Neurorehabilitation Devices
3.5.3. Opportunities
3.5.3.1. Rising Demand of Telerehabilitation
3.5.4. Impact analysis
3.6. Covid-19 Impact analysis on neurorehabilitaion market
CHAPTER 4: NEUROREHABILITATION MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Neuro-Robotic Devices
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Non-Invasive Stimulators
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Brain-Computer Interfaces
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: NEUROREHABILITATION MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Brain Stroke
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Parkinson's Disease
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Multiple Sclerosis
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Spinal Cord Injury (SCI)
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Traumatic Brain Injury
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Cerebral Palsy
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
5.8. Others
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country
CHAPTER 6: NEUROREHABILITATION MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Rehabilitation Centers
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Hospitals
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Clinic
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: NEUROREHABILITATION MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. neurorehabilitation market, by type
7.2.2.1.2. U.S. neurorehabilitation market, by application
7.2.2.1.3. U.S. neurorehabilitation market, by end user
7.2.2.2. Canada
7.2.2.2.1. Canada neurorehabilitation market, by type
7.2.2.2.2. Canada neurorehabilitation market, by application
7.2.2.2.3. Canada neurorehabilitation market, by end user
7.2.2.3. Mexico
7.2.2.3.1. Mexico neurorehabilitation market, by type
7.2.2.3.2. Mexico neurorehabilitation market, by application
7.2.2.3.3. Mexico neurorehabilitation market, by end user
7.2.3. North America market size and forecast, by type
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany neurorehabilitation market, by type
7.3.2.1.2. Germany neurorehabilitation market, by application
7.3.2.1.3. Germany neurorehabilitation market, by end user
7.3.2.2. France
7.3.2.2.1. France neurorehabilitation market, by type
7.3.2.2.2. France neurorehabilitation market, by application
7.3.2.2.3. France neurorehabilitation market, by end user
7.3.2.3. UK
7.3.2.3.1. UK neurorehabilitation market, by type
7.3.2.3.2. UK neurorehabilitation market, by application
7.3.2.3.3. UK neurorehabilitation market, by end user
7.3.2.4. Italy
7.3.2.4.1. Italy neurorehabilitation market, by type
7.3.2.4.2. Italy neurorehabilitation market, by application
7.3.2.4.3. Italy neurorehabilitation market, by end user
7.3.2.5. Spain
7.3.2.5.1. Spain neurorehabilitation market, by type
6.3.2.5.2. Spain neurorehabilitation market, by application
6.3.2.5.3. Spain neurorehabilitation market, by end user
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe neurorehabilitation market, by type
7.3.2.6.2. Rest of Europe neurorehabilitation market, by application
7.3.2.6.3. Rest of Europe neurorehabilitation market, by end user
7.3.3. Europe market size and forecast, by type
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country109
7.4.2.1. Japan
7.4.2.1.1. Japan neurorehabilitation market, by type
7.4.2.1.2. Japan neurorehabilitation market, by application
7.4.2.1.3. Japan neurorehabilitation market, by end user
7.4.2.2. China
7.4.2.2.1. China neurorehabilitation market, by type
7.4.2.2.2. China neurorehabilitation market, by application
7.4.2.2.3. China neurorehabilitation market, by end use
7.4.2.3. Australia
7.4.2.3.1. Australia neurorehabilitation market, by type
7.4.2.3.2. Australia neurorehabilitation market, by application
7.4.2.3.3. Australia neurorehabilitation market, by end user
7.4.2.4. India
7.4.2.4.1. India neurorehabilitation market, by type
7.4.2.4.2. India neurorehabilitation market, by application
7.4.2.4.3. India neurorehabilitation market, by end user
7.4.2.5. South Korea
7.4.2.5.1. South Korea neurorehabilitation market, by Type
7.4.2.5.2. South Korea neurorehabilitation market, by application
7.4.2.5.3. South Korea neurorehabilitation market, by end user
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific neurorehabilitation market, by type
7.4.2.6.2. Rest of Asia-Pacific neurorehabilitation market, by application
7.4.2.6.3. Rest of Asia-Pacific neurorehabilitation market, by end user
7.4.3. Asia-Pacific market size and forecast, by type
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country126
7.5.2.1. Latin America
7.5.2.1.1. Latin America neurorehabilitation market, by type
7.5.2.1.2. Latin America neurorehabilitation market, by application
7.5.2.1.3. Latin America neurorehabilitation market, by end user
7.5.2.2. Middle East and Africa131
7.5.2.2.1. Middle East and Africa neurorehabilitation market, by type
7.5.2.2.2. Middle East and Africa neurorehabilitation market, by application
7.5.2.2.3. Middle East and Africa neurorehabilitation market, by end user
7.5.3. LAMEA market size and forecast, by type
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user
CHAPTER 7: COMPANY PROFILES
7.1. Bioventus (Bioness Inc.)
7.1.1. Company overview
7.1.2. Operating business segments
7.1.3. Product portfolio
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.2. Bionik Laboratories Corporation
7.2.1. Company overview
7.2.2. Operating business segments
7.2.3. Product portfolio
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.3. Ekso Bionics Holdings, Inc.
7.3.1. Company overview
7.3.2. Company snapsho
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Eodyne
7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Product portfolio
7.5. DIH (Hocoma AG)
7.5.1. Company overview
7.5.2. Operating business segments
7.5.3. Product portfolio
7.5.4. Key strategic moves and developments
7.6. Neofect
7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Key strategic moves and developments
7.7. Neuro Rehab VR
7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Product portfolio
7.7.4. Key strategic moves and developments
7.8. ReWalk Robotics Ltd
7.8.1. Company overview
7.8.2. Operating business segments
7.8.3. Product portfolio
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.9. Reha Technology
7.9.1. Company overview
7.9.2. Operating business segments
7.9.3. Product portfolio
7.9.4. Key strategic moves and developments
7.10. BioScience Managers Limited (Rex Bionics Ltd)
7.10.1. Company overview
7.10.2. Operating business segments
7.10.3. Product portfolio
List of Tables
TABLE 01. GLOBAL NEUROREHABILITATION MARKET, BY APPLICATION TYPE, 2020-2030($MILLION)
TABLE 02. NEUROREHABILITATION MARKET FOR NEURO-ROBOTIC DEVICES, BY REGION, 2020-2030($MILLION)
TABLE 03. NEUROREHABILITATION MARKET FOR WEARABLE DEVICES, BY REGION, 2020-2030($MILLION)
TABLE 04. NEUROREHABILITATION MARKET FOR NON-INVASIVE STIMULATORS, BY REGION, 2020-2030($MILLION)
TABLE 05. NEUROREHABILITATION MARKET FOR BRAIN-COMPUTER INTERFACES, BY REGION, 2020-2030($MILLION)
TABLE 06. GLOBAL NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 07. NEUROREHABILITATION MARKET FOR BRAIN STROKE, BY REGION, 2020-2030($MILLION)
TABLE 08. NEUROREHABILITATION MARKET FOR PARKINSON'S DISEASE, BY REGION, 2020-2030($MILLION)
TABLE 09. NEUROREHABILITATION MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020-2030($MILLION)
TABLE 10. NEUROREHABILITATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2020-2030($MILLION)
TABLE 11. NEUROREHABILITATION MARKET FOR TRAUMATIC BRAIN INJURY, BY REGION, 2020-2030($MILLION)
TABLE 12. NEUROREHABILITATION MARKET FOR CEREBRAL PALSY, BY REGION, 2020-2030($MILLION)
TABLE 13. NEUROREHABILITATION MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
TABLE 14. GLOBAL NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 15. NEUROREHABILITATION MARKET FOR REHABILITATION CENTERS, BY REGION, 2020-2030($MILLION)
TABLE 16. NEUROREHABILITATION MARKET FOR HOSPITALS, BY REGION, 2020-2030($MILLION)
TABLE 17. NEUROREHABILITATION MARKET FOR CLINIC, BY REGION, 2020-2030($MILLION)
TABLE 18. NEUROREHABILITATION MARKET, BY REGION, 2020-2030($MILLION)
TABLE 19. NORTH AMERICA NEUROREHABILITATION MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 20. U.S. NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 21. U.S. NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 22. U.S. NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 23. CANADA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 24. CANADA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 25. CANADA NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 26. MEXICO NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 27. MEXICO NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 28. MEXICO NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 29. NORTH AMERICA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 30. NORTH AMERICA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 31. NORTH AMERICA NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 32. EUROPE NEUROREHABILITATION MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 33. GERMANY NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 34. GERMANY NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 35. GERMANY NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 36. FRANCE NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 37. FRANCE NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 38. FRANCE NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 39. UK NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 40. UK NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 41. UK NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 42. ITALY NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 43. ITALY NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 44. ITALY NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 45. SPAIN NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 46. SPAIN NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 47. SPAIN NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION
TABLE 48. REST OF EUROPE NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 49. REST OF EUROPE NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 50. REST OF EUROPE NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 51. EUROPE NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 52. EUROPE NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 53. EUROPE NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 54. ASIA-PACIFIC NEUROREHABILITATION MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 55. JAPAN NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 56. JAPAN NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 57. JAPAN NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 58. CHINA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 59. CHINA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 60. CHINA NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 61. AUSTRALIA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION
TABLE 62. AUSTRALIA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 63. AUSTRALIA NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 64. INDIA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 65. INDIA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 66. INDIA NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 67. SOUTH KOREA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 68. SOUTH KOREA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 69. SOUTH KOREA NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 70. REST OF ASIA-PACIFIC NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 71. REST OF ASIA-PACIFIC NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 72. REST OF ASIA-PACIFIC NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION
TABLE 73. ASIA-PACIFIC NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 74. ASIA-PACIFIC NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 75. ASIA-PACIFIC NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 76. LAMEA NEUROREHABILITATION MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 77. BRAZIL NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 78. BRAZIL NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 79. BRAZIL NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 80. SAUDI ARABIA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 81. SAUDI ARABIA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 82. SAUDI ARABIA NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 83. SOUTH AFRICA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 84. SOUTH AFRICA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 85. SOUTH AFRICA NEUROREHABILITATION MARKET, BY END USER 2020-2030($MILLION)
TABLE 86. REST OF LAMEA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 87. REST OF LAMEA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 88. REST OF LAMEA NEUROREHABILITATION MARKET, END USER, 2020-2030($MILLION)
TABLE 89. LAMEA NEUROREHABILITATION MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 90. LAMEA NEUROREHABILITATION MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 91. LAMEA NEUROREHABILITATION MARKET, BY END USER, 2020-2030($MILLION)
TABLE 92. BIOVENTUS: COMPANY SNAPSHOT
TABLE 93. BIOVENTUS: OPERATING SEGMENTS
TABLE 94. BIOVENTUS: PRODUCT PORTFOLIO
TABLE 95. BIOVENTUS: KEY DEVELOPMENTS
TABLE 96. BIONIK LABORATORIES: COMPANY SNAPSHOT
TABLE 97. BIONIK LABORATORIES: OPERATING SEGMENTS
TABLE 98. BIONIK LABORATORIES: PRODUCT PORTFOLIO
TABLE 99. BIONIK LABORATORIES: KEY DEVELOPMENTS
TABLE 100. EKSO BIONICS: SNAPSHOT
TABLE 101. EKSO BIONICS: OPERATING SEGMENTS
TABLE 102. EKSO BIONICS: PRODUCT PORTFOLIO
TABLE 103. EKSO BIONICS: KEY DEVELOPMENTS
TABLE 104. EODYNE: COMPANY SNAPSHOT
TABLE 105. EODYNE: OPERATING SEGMENTS
TABLE 106. EODYNE: PRODUCT PORTFOLIO
TABLE 107. DIH: COMPANY SNAPSHOT
TABLE 108. DIH: OPERATING SEGMENTS
TABLE 109. DIH: PRODUCT PORTFOLIO
TABLE 110. DIH: KEY DEVELOPMENTS
TABLE 111. NEOFECT: COMPANY SNAPSHOT
TABLE 112. NEOFECT: OPERATING SEGMENTS
TABLE 113. NEOFECT: PRODUCT PORTFOLIO
TABLE 114. NEOFECT: KEY DEVELOPMENTS
TABLE 115. NEURO REHAB VR: COMPANY SNAPSHOT
TABLE 116. NEURO REHAB VR: OPERATING SEGMENTS
TABLE 117. NEURO REHAB VR: PRODUCT PORTFOLIO
TABLE 118. NEURO REHAB VR: KEY DEVELOPMENTS
TABLE 119. REWALK ROBOTICS: COMPANY SNAPSHOT
TABLE 120. REWALK ROBOTICS: OPERATING SEGMENTS
TABLE 121. REWALK ROBOTICS: PRODUCT PORTFOLIO
TABLE 122. REWALK ROBOTICS: KEY DEVELOPMENTS
TABLE 123. REHA TECHNOLOGY: COMPANY SNAPSHOT
TABLE 124. REHA TECHNOLOGY: OPERATING SEGMENTS
TABLE 125. REHA TECHNOLOGY: PRODUCT PORTFOLIO
TABLE 126. REHA TECHNOLOGY: KEY DEVELOPMENTS
TABLE 127. BIOSCIENCE: COMPANY SNAPSHOT
TABLE 128. BIOSCIENCE: OPERATING SEGMENTS
TABLE 129. BIOSCIENCE: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR NEURO-ROBOTIC DEVICES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 02. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR WEARABLE DEVICES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 03. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR NON-INVASIVE STIMULATORS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 04. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR BRAIN-COMPUTER INTERFACES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 05. COMPARATIVE ANALYSIS NEUROREHABILITATION MARKET FOR BRAIN STROKE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 06. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 07. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 08. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR SPINAL CORD INJURY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 09. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR TRAUMATIC BRAIN INJURY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS NEUROREHABILITATION MARKET FOR CEREBRAL PALSY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR REHABILITATION CENTERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF NEUROREHABILITATION MARKET FOR CLINIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. BIOVENTUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 16. BIOVENTUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 17. BIOVENTUS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 18. BIONIK LABORATORIES: NET SALES, 2019–2021 ($MILLION)
FIGURE 19. EKSO BIONICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 20. EKSO BIONICS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 21. EKSO BIONICS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 22. REWALK ROBOTICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 23. REWALK ROBOTICS: REVENUE SHARE BY REGION, 2020 (%)

Companies Mentioned

  • Bionik Laboratories Corp.
  • BioScience Managers Ltd (Rex Bionics Ltd)
  • Bioventus (Bioness Inc.)
  • DIH (Hocoma AG)
  • Ekso Bionics Holdings Inc.
  • Eodyne
  • Neofect
  • Neuro Rehab VR
  • Reha Technology AG
  • ReWalk Robotics Ltd

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...